AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05617482 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ilioinguinal, iliohypogastric nerve blocks
Description: In ilioinguinal-iliohypogastric block group, the probe will be placed medial to the lateral one-third of the line joining the umbilicus and the anterior superior iliac spine (ASIS). The anterior superior iliac crest, iliacus muscle, internal oblique, transverses abdominis, and the ILIH nerves between them will be identified. After appreciating the sonoanatomy, the ILIH nerve will be approached with the 23-gauge Quincke spinal needle through in-plane technique and 10 ml of 0.25% bupivacaine will be injected all around and the drug spread will be appreciated.
Study NCT05617482 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TAP block
Description: In TAP block group, the probe will be placed perpendicular to the mid-axillary line between the iliac crest and the subcostal margin and the three abdominal muscle layers will be identified, and the transverses abdominis plane will be located between the internal oblique and the transverse abdominis muscle. The TAP will be approached through in-plane technique using a 23-gauge Quincke spinal needle attached to a 20 ml syringe of 0.25% bupivacaine will be injected and the drug spread in the plane will be observed.
Study NCT05617482 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus lumborum block
Description: For the QLB, the transducer will be placed at the level of the anterosuperior iliac spine and will move cranially until the 3 abdominal wall muscles will be clearly identified. The external oblique muscle will be followed posterolaterally until its posterior border was visualized (hook sign), leaving underneath the internal oblique muscle, like a roof over the quadratus lumborum muscle. The probe will be tilted down to identify a bright hyperechoic line that corresponded with the middle layer of he thoracolumbar fascia. The needle (21 gauge) will be inserted in plane from anterolateral to posteromedial. The optimal point of injection for the QL block will be determined over the lumbar interfacial triangle using hydrodissection.
Study NCT05178667 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High dose
Description: Food supplements are consumed during 3 months by healthy volunteers.
Study NCT05178667 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low dose
Description: Food supplements are consumed during 3 months by healthy volunteers.
Study NCT05178667 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Food supplements are consumed during 3 months by healthy volunteers.
Study NCT05630482 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Family Foundations
Description: Healthy Family Foundations Curriculum
Study NCT05630482 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care
Study NCT06318715 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: modified deep extubation (mDE)
Description: The proposed study is to compare a modified DE technique, which is regularly used for low-risk patients by staff anesthesiologists at our institution, to a standard awake extubation.
Study NCT06318715 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: standard awake extubation
Description: awake extubation (AE) is still considered the standard practice.
Study NCT05453123 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: telerehabilitation
Description: examine the effect of the text message platform (WhatsApp) on the adherence to home exercise programs, pain and physical function among middle age and older adults with knee OA in two public hospitals in Riyadh city, Saudi Arabia.
Study NCT05453123 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: telerehabilitation
Description: examine the effect of the text message platform (WhatsApp) on the adherence to home exercise programs, pain and physical function among middle age and older adults with knee OA in two public hospitals in Riyadh city, Saudi Arabia.
Study NCT05369273 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: intra-articular injection
Description: intra-articular injection
Study NCT05369273 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intra-articular injection
Description: intra-articular injection
Study NCT05369273 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: RMI SCANS
Description: AT 1 MONTHS BEFORE THE INTERVENTION
Study NCT05369273 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: RMI SCANS
Description: AT 1 MONTHS BEFORE THE INTERVENTION
Study NCT05369273 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: RMI SCANS
Description: AT 1MONTH AFTER THE INTERVENTION
Study NCT05369273 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RMI SCANS
Description: AT 1MONTH AFTER THE INTERVENTION
Study NCT05369273 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: RMI SCAN
Description: AT 6 MONTHS AFTER THE INTERVENTION
Study NCT05369273 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RMI SCAN
Description: AT 6 MONTHS AFTER THE INTERVENTION
Study NCT05972031 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Person-centred integrated care intervention
Description: See arm description.
Study NCT04685057 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intervention with a daily dose of placebo for 6 months
Study NCT04685057 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Intervention with a daily dose of probiotic for 6 months
Study NCT04685057 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Follow-up probiotic
Description: Intervention with a daily dose of probiotic for 6 months
Study NCT04685057 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Follow-up probiotic
Description: Intervention with a daily dose of probiotic for 6 months
Study NCT06384196 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Identity-Based Transdiagnostic Therapy (IBTT)
Description: In this study, IBTT is applied in 16, one-hour weekly sessions based on contemporary constructivist psychotherapy enhanced with the technological platform EYME-Explore Your Meanings to enable the immersive exploration of the patient's self-identity. Although it could be applied to other populations, IBTT has been designed to improve the mental health of late adolescents and young people.
Study NCT06384196 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Unified Protocol
Description: In this study, the UP is applied in 16, one-hour weekly sessions based on contemporary cognitive and behavioral techniques.
Study NCT06132126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3938577
Description: Administered SC.
Study NCT06132126 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC.
Study NCT06132126 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin degludec
Description: Administered SC.
Study NCT04937803 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug-coated balloon
Description: Drug-coated balloon is a fast-exchange balloon dilatation catheter, used to treat coronary artery stenosis lesions and improve myocardial blood flow.
Study NCT04937803 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zotarolimus-Eluting Coronary Stent
Description: Zotarolimus-Eluting Coronary Stent is treated for coronary artery stenosis lesions .
Study NCT06164080 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: participants receiving Corticosteroid
Description: Pregnant women using antenatal corticosteroids for any reason before 34 weeks
Study NCT04956172 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NeuroCatch Platform 2
Description: To elicit the ERP components of interest in this study (N100, P300, N400), proprietary auditory stimulus sequences will be administered using the NeuroCatch Platform 2, an investigational medical device. Each sequence consists of tones and word pairs to elicit the various components of interest. The NeuroCatch Platform 2 consists of a computerized acquisition software which presents the stimulus, acquires the data and presents the amplitude and latency values of the ERP components (N100, N400, P300)
Study NCT04956172 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroCatch Platform 2
Description: To elicit the ERP components of interest in this study (N100, P300, N400), proprietary auditory stimulus sequences will be administered using the NeuroCatch Platform 2, an investigational medical device. Each sequence consists of tones and word pairs to elicit the various components of interest. The NeuroCatch Platform 2 consists of a computerized acquisition software which presents the stimulus, acquires the data and presents the amplitude and latency values of the ERP components (N100, N400, P300)
Study NCT05534256 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sit Less Program
Description: The intervention group will target a 120 minute per day reduction in sedentary behavior using an objective activity monitor and mHealth. Outcomes will be measured at baseline and post-intervention
Study NCT04708210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI319
Description: Iv infusion day 1 of every 14 or 21 days in Phase Ia until disease progression or loss of clinical benefit.
Study NCT04252768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eftilagimod Alpha
Description: The chemo-immunotherapy phase consists of 6 cycles of 4 weeks each. During each cycle the subject will receive 30 mg efti subcutaneously on Day 1 and 15 in a 28-day (4-week) cycle. Efti will always be given after paclitaxel. The maintenance phase comprises 6 visits with 4 weekly intervals; during each such visit 30 mg efti is given subcutaneosuly as monotherapy.
Study NCT04252768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: The chemo-immunotherapy phase consists of 6 cycles of 4 weeks each. During each cycle the subject will receive 80 mg/m2 paclitaxel intravenously on Day 1, 8 and 15.
Study NCT06448676 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A
Description: Head-to-head comparison of all commercially available botulinum neurotoxin type A products
Study NCT05179135 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Postprandial exercise of different modalities
Description: Physical exercise performed 60 minutes after a standardized meal, of different modalities (4 different modalities will be examined, as described in the Arms)
Study NCT05179135 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postprandial exercise of different modalities
Description: Physical exercise performed 60 minutes after a standardized meal, of different modalities (4 different modalities will be examined, as described in the Arms)
Study NCT05356897 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Given IV
Study NCT05356897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine and Tipiracil Hydrochloride
Description: Given PO
Study NCT05356897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib
Description: Given PO
Study NCT05965258 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac magnetic resonance (CMR)
Description: Cardiac magnetic resonance (CMR) at 6 months. If referred to MitraClip, CMR will be performed at 6 months from the procedure.
Study NCT05647408 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: The nominal doses were similar, volunteers were randomly assigned to receive a single dose of DXM by IV bolus of 1.5 mL (equivalent to 6 mg of dexamethasone) or the same dose intranasally by using a Mucosal Atomization Device (MAD Nasal). allowing direct pharmacokinetic comparison without dose normalization. Venous blood samples were obtained via an indwelling catheter before administration and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 12 and 24 h for DXM. Plasma was separated and frozen at -70 °C for further analysis.
Study NCT05753371 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Hydrochloride 500 MG
Description: Metformin is an antihyperglycemic drug used in the management of type-2 diabetes. Metformin hydrochloride improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
Study NCT05753371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride 500 MG
Description: Metformin is an antihyperglycemic drug used in the management of type-2 diabetes. Metformin hydrochloride improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
Study NCT05660486 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aromatherapy
Description: Participants in this group will receive 2-3 drops of 100% pure Lavandula angustifolia essential oil applied to a surgical mask pre-procedure for aromatherapy.
Study NCT05660486 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants in this group will receive 2-3 drops of water applied to a surgical mask pre-procedure.
Study NCT06524206 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Awareness, Courage and Love Intervention
Description: Derived from Functional Analytic Psychotherapy (FAP), the Awareness, Courage, and Love (ACL) Intervention brings the FAP principles to a broader population. In the ACL model, awareness is defined as engaging in mindful awareness of one's self (feelings, needs, values), other individuals, and the context in which interactions are taking place. Courage is defined as engaging in authentic, vulnerable self-disclosures (e.g. struggles, appreciation), and asking for what one wants and needs. Love is defined as providing empathically accurate responsiveness, including provision of safety, validation, and giving the other person what they have asked for when possible.
Study NCT04157231 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Acute stroke care Intervention arm
Description: Training and education of the site staff about the treatment protocol for the different components of the management plan will be provided on two occasions. The aim of these sessions will be to educate stroke champions and other site staff on the management protocols. Available training resources will be accessed (including online materials) and simulation training will be used. New skills such as dysphagia assessment will be emphasized based on existing knowledge and competencies. After training, staff will have another assessment (Post-test) in order to determine whether they have been adequately trained and are able to adhere to the essential acute stroke care management plan. A standardised Power Point presentation and accompanying handouts will be made available for further use in the ward.~Refresher training will be provided monthly during the intervention.
Study NCT05795244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: - Nivolumab 480 mg/every 4 weeks/IV infusion/6 cycles
Study NCT04456569 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Geniculate Artery Embolization
Description: All patients within the embolization group will undergo unilateral angiography and embolization of the appropriate treatment limb geniculate arteries. For patients with bilateral disease the more clinically symptomatic side will be chosen as the treatment/control knee.
Study NCT05074485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anakinra
Description: intravenous injection of 100 milligrams anakinra
Study NCT05074485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: intravenous injection of 1 milliliter normal saline
Study NCT05074485 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nociceptive pain challenge
Description: The experimental, standardized, nociceptive pain challenge will induce a moderate level of sustained pain. The pain challenge involves a masseteric injection in the left or right jaw muscle of normal saline (0.15 ml bolus of 0.9% normal saline) over a 15 second period followed by continuous infusion via a closed loop infusion system for 20 minutes.
Study NCT06375161 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD19-CAR-T cells
Description: Before cell infusion, Investigator may decide, based on necessity, whether to administer prophylactic medication, which may include options such as acetaminophen and diphenhydramine, or H1 antihistamines, among others.~Subjects are allowed to receive adequate supportive care after anti-CD19-CAR-T cell infusion, including blood transfusions and blood products, antibiotic therapy, antiemetics, antidiarrheals, analgesics, etc.
Study NCT05786430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib/Pemetrexed/Carboplatin
Description: Combination of lazertinib 240 mg (80 mg, 3 tablets) and pemed-S + carboplatin. Once a day lazertinib 240 mg pemed-S: 500mg/m2 q3w carboplatin: AUC5 q3w (only administered up to 4 cycles)
Study NCT05537831 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: The ultrasound will be used to assist with the delivery of a hematoma block in patients with distal forearm fractures.
Study NCT04850794 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision Support Tool
Description: The decision support tool is an observational checklist with recommendations for specific specialist referrals based on what the provider observed during the feeding evaluation.
Study NCT04870684 — intervention group
Intervention type: OTHER
Intervention: thromboelastometry test
Description: This study does not modify the usual care of the patient. Only 5 citrated tubes (maximum 15 mL of blood) are collected in addition to the initial emergency department sample (routine care). The patient's care follows the classic thrombolysis alert pathway. There is no additional complementary examination or additional neurological evaluation. Clot formation kinetics will be evaluated by thromboelastometry to determine the predictive parameters of revascularization. Clot formation and lysis parameters as well as revascularization according to thrombo-inflammation processes will be studied.
Study NCT05034120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XZP-3621
Description: Administer a single dose of XZP-3621 tablet after a low-fat meal.
Study NCT05034120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XZP-3621
Description: Cycle1(D1-D9): Administer the XZP-3621 tablet on an empty stomach in a single dose on Day1; Cycle2(D10-D18): Administer the XZP-3621 tablet after a high-fat meal in a single dose on Day10; Cycle3(D19-D27): Administer the XZP-3621 tablet after a standard meal in a single dose on Day19.
Study NCT05034120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XZP-3621
Description: Cycle1(D1-D9) : Administer the XZP-3621 tablet after a high-fat meal in a single dose on Day1; Cycle2(D10-D18): Administer the XZP-3621 tablet after a standard meal in a single dose on Day10; Cycle3(D19-D27): Administer the XZP-3621 tablet after on an empty stomach in a single dose on Day19.
Study NCT05034120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XZP-3621
Description: Cycle1(D1-D9): Administer the XZP-3621 tablet after a standard meal in a single dose on Day1; Cycle2(D10-D18): Administer the XZP-3621 tablet on an empty stomach in a single dose on Day10; Cycle3(D19-D27): Administer the XZP-3621 tablet after a high-fat meal in a single dose on Day19.
Study NCT05034120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XZP-3621
Description: Cycle1(D1-D9) : Administer the XZP-3621 tablet on an empty stomach in a single dose on Day1; Cycle2(D10-D18): Administer the XZP-3621 tablet after a standard meal in a single dose on Day10; Cycle3(D19-D27): Administer the XZP-3621 tablet after a high-fat meal in a single dose on Day19.
Study NCT05034120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XZP-3621
Description: Cycle1(D1-D9): Administer the XZP-3621 tablet after a high-fat meal in a single dose on Day1; Cycle2(D10-D18): Administer the XZP-3621 tablet on an empty stomach in a single dose on Day10; Cycle3(D19-D27): Administer the XZP-3621 tablet after a standard meal in a single dose on Day19.
Study NCT05034120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XZP-3621
Description: Cycle1(D1-D9): Administer the XZP-3621 tablet after a standard meal in a single dose on Day1; Cycle2(D10-D18): Administer the XZP-3621 tablet after a high-fat meal in a single dose on Day10; Cycle3(D19-D27): Administer the XZP-3621 tablet on an empty stomach in a single dose on Day19.
Study NCT04754308 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Spirometry
Description: The method of examination, Spirometry, is non-invasive (i.e. not an intervention that involves penetration into the body by means of incisions or injections.). It is a routine examination and there are no risks, adverse reactions, or discomforts associated with the examination.
Study NCT04961658 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEM00220
Description: Cryopreserved allogeneic, enhanced MSCs administered as a single intravenous infusion
Study NCT05025046 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Thyroscan
Description: To evaluate the accuracy of Thyroscan in the differential diagnosis of benign and malignant thyroid nudules with abnormal ultrasound features.